Keeping Microfluidic Product Development Costs Down

Cost-effective development of microfluidic and IVD products is not achieved by simply reducing spend—it is achieved through informed decision-making, early risk reduction, and strategic planning across the entire development lifecycle.

At Device Scope, we support teams in optimising development efficiency while maintaining technical robustness, regulatory compliance, and commercial viability.

Start with Clear Requirements & Investor Alignment

A strong foundation begins with a clear definition of product requirements, including:

• Clinical and user needs

• Performance targets

• Regulatory pathway

• Commercial objectives

Equally important is alignment with investor milestones and funding expectations. Development activities should be structured to deliver meaningful technical and commercial de-risking at each stage, ensuring that progress is both measurable and compelling to stakeholders.

A lack of clarity at this stage often leads to scope creep, rework, and missed milestones, all of which significantly increase development costs.

Account for Assay Translation Early

One of the most underestimated cost drivers in microfluidic IVD development is the translation of a laboratory-based assay into a robust, manufacturable microfluidic cartridge format.

An assay that performs well under controlled laboratory conditions often requires significant adaptation to function reliably within the constraints of a microfluidic system. These constraints introduce additional variables that can directly impact assay performance, reproducibility, and ultimately product viability.

Key technical considerations include:

Surface-to-volume effects

Microfluidic systems inherently have high surface-area-to-volume ratios, increasing the influence of non-specific binding, adsorption, and surface chemistry interactions, which can adversely affect assay sensitivity and specificity.

Material and process compatibility

Materials and manufacturing processes used in cartridge fabrication (e.g. injection moulding, bonding methods) must be compatible with assay reagents and conditions, avoiding issues such as leachables, adsorption, or reagent degradation.

Microfluidic functional performance

The reliability and consistency of pumping, valving, dosing, mixing, separation, and flow sequencing directly impact assay execution. Variability in these functions can lead to performance drift or failure.

Reagent formulation and shelf-life requirements

Transitioning to a cartridge format often necessitates changes in reagent format (e.g. liquid, dried, or lyophilised) and careful consideration of stability, storage conditions, and packaging integration to meet shelf-life requirements.

To control cost and reduce development risk, assay translation should begin early and often progresses in parallel with cartridge development, supported by dedicated and staged work-packages:

Early assay integration and feasibility assessment.

Initial evaluation of the assay protocol, performance characteristics, product requirements and microfluidic concept, thereby identifying key risks and integration challenges.

Proof-of-principle (PoP) microfluidic devices

Simple test platforms designed to isolate and characterise critical functions (e.g. fluid handling, dosing, mixing, detection). These enable rapid learning, support assay optimisation, and define key performance parameters before system complexity increases.

Integrated functional prototypes

Devices that bring together multiple subsystems to evaluate end-to-end assay performance in a representative cartridge format, enabling system-level optimisation and often further assay optimisation.

Shelf-life and stability studies

Assessment of reagent stability within the cartridge and packaging environment, including evaluation of formulation strategies, storage conditions, and degradation mechanisms.

By addressing assay integration early and systematically, development teams can reduce uncertainty, accelerate decision-making, and avoid costly downstream redesigns.

Plan for Parallel Development Programmes

Many IVD systems require the simultaneous development of assay, cartridge, and instrument platforms. While parallel development accelerates time-to-market, it introduces complex interdependencies.

Effective cost control requires:

• Clear identification of technical dependencies between subsystems

• Early definition of critical inputs and interfaces

• Well documented project and technical risks

• Structured development planning to avoid bottlenecks

  
  

Without this coordination, teams often encounter idle development time, duplicated effort, or late integration failures, all of which increase cost and risk.

Test Early and Often

Early testing is one of the most powerful tools for cost control.

By using rapid, low-cost prototypes, teams can:

• Validate core assumptions

• Identify design flaws early

• Optimise cartridge and assay performance

• Refine system architecture before committing to expensive tooling or processes with long lead times

Rapid prototyping of Proof-of-principle and integrated prototypes allow key questions to be answered quickly, reducing the likelihood of expensive late-stage design changes.

The principle is simple:

The earlier a problem is identified, the lower the cost to resolve it.

Implement Design for Manufacture (DFM) from the Start

Designing with manufacturing in mind from day one is critical to avoiding unnecessary cost escalation.

Early DFM activities should include:

• Material selection aligned with scalable processes

• Simplified part geometries and assembly methods

• Engagement with manufacturing partners and suppliers

Involving manufacturing expertise early ensures that designs are practical, scalable, and cost-efficient, reducing the need for redesign or specialised tooling later in development.

Plan for Manufacturing Scale-Up from the Outset

Cost-effective development requires a clear path from: prototype → pilot production → full-scale manufacturing

Key considerations include:

• Selection of manufacturing processes that can scale economically

• Early assessment of production volumes and cost-of-goods targets

• Planning for tooling, automation, and supply chain requirements

By integrating scale-up considerations early, teams avoid costly redesigns when transitioning from development to production.

Apply Quality Management Systems Pragmatically

Implementing a Quality Management System (QMS) is both a regulatory requirement and a cornerstone of robust product development.

However, the timing and level of implementation of design controls is critical.

• Applying full design controls too early can slow innovation and increase administrative burden

• Applying them too late can introduce compliance risks and rework

A phased approach allows teams to:

• Maintain agility during early feasibility stages

• Introduce formal controls as the design matures and risks reduce

This ensures compliance without compromising development efficiency.

A Structured Approach to Cost Reduction

Reducing development costs is not about cutting corners—it is about working smarter across the entire development process.

A structured approach typically includes:

• Development readiness assessments

• Robust development planning

• Early risk identification and mitigation

• Design for manufacture integration

• Defined scale-up strategies

Final Thoughts

Microfluidic and IVD product development is inherently complex, but with the right strategy, it is possible to reduce cost, minimise risk, and accelerate time-to-market.

At Device Scope, we work with clients to:

• Identify and mitigate technical and commercial risks early

• Align development with investor and regulatory expectations

• Deliver efficient, scalable, and commercially viable products

If you are looking to optimise your development programme, a structured, risk-based approach is the most effective way to control cost while maintaining quality and performance.